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Background: The transplantation of neural stem/progenitor cells (NS/PCs) at the sub-acute phase of spinal cord
injury, but not at the chronic phase, can promote functional recovery. However, the reasons for this difference and
whether it involves the survival and/or fate of grafted cells under these two conditions remain unclear. To address
this question, NS/PC transplantation was performed after contusive spinal cord injury in adult mice at the sub-acute
and chronic phases.
Results: Quantitative analyses using bio-imaging, which can noninvasively detect surviving grafted cells in living
animals, revealed no significant difference in the survival rate of grafted cells between the sub-acute and chronic
transplantation groups. Additionally, immunohistology revealed no significant difference in the differentiation
phenotypes of grafted cells between the two groups. Microarray analysis revealed no significant differences in the
expression of genes encoding inflammatory cytokines or growth factors, which affect the survival and/or fate of
grafted cells, in the injured spinal cord between the sub-acute and chronic phases. By contrast, the distribution of
chronically grafted NS/PCs was restricted compared to NS/PCs grafted at the sub-acute phase because a more
prominent glial scar located around the lesion epicenter enclosed the grafted cells. Furthermore, microarray and
histological analysis revealed that the infiltration of macrophages, especially M2 macrophages, which have
anti-inflammatory role, was significantly higher at the sub-acute phase than the chronic phase. Ultimately, NS/PCs
that were transplanted in the sub-acute phase, but not the chronic phase, promoted functional recovery compared
with the vehicle control group.
Conclusions: The extent of glial scar formation and the characteristics of inflammation is the most remarkable
difference in the injured spinal cord microenvironment between the sub-acute and chronic phases. To achieve
functional recovery by NS/PC transplantation in cases at the chronic phase, modification of the microenvironment
of the injured spinal cord focusing on glial scar formation and inflammatory phenotype should be considered.
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The injured spinal cord exhibits little spontaneous re-
covery and, as a result, many spinal cord injury (SCI)
patients suffer from permanent functional impairments,
such as motor and sensory dysfunction, and bladder and
rectal disturbance. However, some previous reports have
shown that neural stem/progenitor cells (NS/PCs) trans-
planted into the injured spinal cord of rodents [1-6] and
non-human primates [7], 7–10 days post-injury (DPI),
promote functional recovery after SCI. These reports in-
dicate that NS/PC transplantation has therapeutic po-
tential for SCI when performed during the sub-acute
phase. However, patients continue to seek new therapies
for SCI many years after their original injury, and most
are therefore in the chronic phase. Although many
researchers have sought to achieve functional recovery
at the chronic phase of SCI by NS/PC transplantation,
with one exception [8], no significant recovery of motor
function has been obtained in animal models of chronic-
phase SCI [9-12]. Despite differences in the survival rate,
the cell types derived from the grafted NS/PCs and the
distribution of grafted cells transplanted at the sub-acute
versus the chronic phase remain unknown. Thus, it
remains unanswered as to why grafted NS/PCs do not
exert therapeutic benefits in the injured spinal cord at
the chronic phase. To address this question, this study
analyzed fetus-derived NS/PCs transplanted into the
injured spinal cord of mice at 9 DPI and 42 DPI.
To assess the survival rate of grafted cells, we per-
formed quantitative analysis using bioluminescence im-
aging (BLI) on a weekly basis until 42 days after
transplantation. BLI is a powerful tool for the detection
of exclusively living grafted cells that stably express
luciferase in living animals after administration of luci-
ferin, the luciferase substrate, because the luciferin-
luciferase reaction depends on oxygen and ATP [13]. In
this study, no significant difference in the survival rate
of grafted cells between the sub-acute and chronic
transplanted (TP) groups was observed at each experi-
mental time point. Immunohistology also revealed no
significant difference in the differentiation pattern of
grafted NS/PCs between the two groups. In addition,
inflammatory cytokines and growth factors, which influ-
ence the survival rate and differentiation characteristics
of grafted cells, were expressed at similar levels at both
phases. By contrast, the grafted cells were distributed
broadly from the epicenter to rostral and caudal sites in
the sub-acute TP group, whereas they remained near
the lesion epicenter, due to extensive glial scarring, in
the chronic TP group. Moreover, prominent macro-
phages distributed at and around the lesion epicenter in
the sub-acute phase by immunohistochemistry, and
microarray analysis demonstrated that the expression of
Arginase-1, which is associated with M2 macrophages,was up-regulated significantly at the sub-acute phase
than the chronic phase. These findings indicated that
the characteristics of post-SCI inflammation are differ-
ent between the sub-acute and chronic phases.
Consequently, the grafted NS/PCs did not promote
any motor functional or histological recovery in the
chronic TP group, while the sub-acute TP group demon-
strated significant recovery compared with the vehicle
control group. Taken together, these data suggest that a
combination therapy of NS/PC transplantation with con-
trol of glial scar formation or inflammatory reaction may
be critical to achieving functional recovery for chronic
SCI.
Results
In vitro characterization of transgenic mouse-derived NS/
PCs that ubiquitously express fluorescent protein-fused
luciferase (ffLuc)-cp156
To identify and monitor the grafted cells by bio-imaging,
a transgenic mouse that ubiquitously expresses ffLuc-
cp156 was previously developed [14]. NS/PCs derived
from this transgenic mouse showed strong and stable
emission of ffLuc-cp156 in vitro (Figure 1A, B). The
number of NS/PCs and the photon counts measured by
BLI were significantly correlated (Figure 1B, C).
We proceeded to perform differentiation and prolifera-
tion assays of these NS/PCs in vitro. The NS/PCs differen-
tiated into βIII tubulin (Tuj-1)+ neurons (21.0 ± 0.5%), glial
fibrillary acidic protein (GFAP)+ astrocytes (63.0 ± 1.5%),
and 2’3’-cyclic nucleotide 3’-phosphodiesterase (CNPase)+
oligodendrocytes (10.4 ± 0.5%) in vitro (Figure 1D, E). ATP
production, an indirect measurement, was used to assess
NS/PC proliferative ability [15]. The doubling time of the
NS/PCs was 28.8 ± 0.8 h. The differentiation rate and pro-
liferative ability of NS/PCs obtained from the transgenic
mice were equivalent to those previously reported for wild-
type NS/PCs [16,17].
Comparison of the injured spinal cord microenvironment
between the sub-acute and chronic phases
To clarify differences in the microenvironment of the
injured spinal cord between the sub-acute and chronic
phases, histological analyses of spinal cord tissues at 9
DPI and 42 DPI were performed. Spinal cord atrophy
and glial scar formation were more prominent at and
around the lesion epicenter at 42 DPI than at 9 DPI
(Figure 2A). A significantly larger CS56+ chondroitin
sulfate proteoglycan (CSPG) area was detected at the le-
sion site at 42 DPI than at 9 DPI (Figure 2A, B). Further-
more, Iba1+ macrophages infiltrated area was more
prominent at the lesion site at 9 DPI but not at 42 DPI
(Figure 2A, C).
To analyze the gene expression profile in the
injured spinal cord, we performed microarray analysis
Figure 1 In vitro characterization of the NS/PCs derived from transgenic mice that ubiquitously express ffLuc-cp156. A, Fluorescence
image showing NS/PCs derived from fetal transgenic mice expressing the fluorescent protein cp156-Venus, which is originally modified from GFP.
B, Bioluminescent signals originating from the luciferase were detected in the NS/PCs by BLI. C, The number of NS/PCs was significantly
correlated with the measured photon count by BLI. Values are means ± SEM (n = 3). D, Tertiary NS/PCs differentiated into Tuj-1+ neurons, GFAP+
astrocytes, and CNPase+ oligodendrocytes in vitro. E, Quantitative analysis of Tuj-1+ neurons, GFAP+ astrocytes, and CNPase+ oligodendrocytes
in vitro. Values are means ± SEM (n = 5). Scale bar: 100 μm in (A) and 50 μm in (D).
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profile of spinal cord tissues at 9 DPI and 42 DPI. As
a control, samples of uninjured naïve spinal cord were
prepared. Principal component analysis (PCA) of all
the microarray data revealed that the samples of the
intact, 9 DPI and 42 DPI groups were clustered at dif-
ferent locations (Figure 2D). Hierarchical clustering of
the target genes, which were narrowed down by cut-
off values for expression levels and by fold change,
revealed that the gene expression profiles of both
injured groups were dramatically different from that
of the intact group. Furthermore, the gene expression
pattern at 9 DPI was similar to that at 42 DPI, but
the magnitude of changes in gene expression differed
between the two injury groups. At 9 DPI, the magni-
tude of gene expression changed more remarkably
than that at 42 DPI (Figure 2E).
Subsequently, we focused on individual gene expres-
sion levels. No significant differences were observed in
the expression levels of genes for individual inflamma-
tory cytokines or growth factors between the two injury
groups (Figure 2F, G). By contrast, the expression of
CD36 and CD68, which are expressed on monocytes
and macrophages, was significantly elevated at 9 DPI(Figure 2H). These results were consistent with the
immunostaining results for Iba1 (Figure 2A, C). Interest-
ingly, the expression of arginase-1, which is associated
with anti-inflammatory M2 macrophages, was also sig-
nificantly higher at 9 DPI than at 42 DPI, whereas no
significant differences were observed in the expression
levels of genes associated with pro-inflammatory M1
macrophages, such as CD86 or inducible nitric oxide
synthase (iNOS). Consistent with these findings, immu-
nohistological analysis revealed more Iba1 and arginase-
1 double-positive cells at 9 DPI (14.1 ± 1.5%) than at 42
DPI (0.9 ± 0.4%) (Figure 2I, J).
We also evaluated the phagocytic activity of the
macrophages recruited into the injured spinal cord
by performing immunohistochemistry for LAMP2, a
marker for endosomes or lysosomes. At 9 DPI, sub-
stantial numbers of infiltrating Iba1, arginase-1, and
LAMP2 triple-positive cells were observed at and
near the lesion epicenter. In contrast, only a small
amount of LAMP2-positive phagocytes were localized
to the lesion epicenter at 42 DPI (Figure 2I). In
addition, no significant expression of myeloperoxi-
dase, a marker of neutrophils, was observed at either
9 DPI or 42 DPI (Figure 2H).
Figure 2 Comparison of the microenvironment of the injured spinal cord at 9 DPI versus 42 DPI. A, Representative images of HE staining
and immunofluorescence staining for GFAP, CS56, and Iba1 in sagittal sections. B, CSPGs accumulation was more prominent at the lesion site at
42 DPI than at 9 DPI. Values are means ± SEM (n = 3). *P < 0.05. C, More Iba1-positive cells were distributed at the lesion site at 9 DPI than at 42
DPI. Values are means ± SEM (n = 3). *P < 0.05. D, Overview of all the microarray data by PCA. The samples of each group were clustered at
different locations on 3D visualization. E, Hierarchical clustering analysis showed that the gene expression pattern at 9 DPI was similar to that at
42 DPI. However, the magnitude of changes in gene expression differed between the two injury groups. Green tiles show downregulated genes
and red tiles indicate upregulated genes. F-H, Gene expression signals of cytokines (F), growth factors (G), and markers of inflammatory cells (H)
at 9 DPI and 42 DPI. The gene expression levels of markers associated with microglia/macrophages significantly differed between 9 DPI and 42
DPI, but those of all cytokines and growth factors did not. Data are the mean fold-change values versus intact samples. Values are means ± SEM
(n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. I, Representative images of immunofluorescence staining for Iba1, arginase-1, and LAMP2 in
sagittal sections of the lesion epicenter at 9 DPI and 42 DPI. Arrows: Iba1+/arginase-1+/LAMP2+ triple-positive cells. J, At the lesion epicenter,
more Iba1+/arginase-1+ M2 macrophages had infiltrated at 9 DPI compared with 42 DPI. Values are means ± SEM (n = 3). **P < 0.01. Scale
bar: 1000 μm in (A) and 50 μm in (J).
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phenotypes of the grafted NS/PCs between the sub-acute
and chronic TP groups
BLI analysis only detects luminescent photon signals
from living cells, and the number of NS/PCs and the
photon count in vitro were significantly correlated. To
investigate whether similar correlativity was observed
in vivo, various numbers of NS/PCs (approximate
range 2.5 × 104 to 5 × 105 cells) were transplanted
into the intact spinal cord of mice (Figure 3A). TheseFigure 3 Survival rate and differentiation phenotype of grafted cells
BLI of naïve mice transplanted with various numbers of NS/PCs. B, The num
correlated in vivo. Values are means ± SEM (n = 3). C, Representative in vivo
after transplantation. D, Quantitative analysis using BLI revealed no significa
acute and chronic TP groups up to 42 days after transplantation. Values are
neurons, GFAP+ astrocytes, and APC+ oligodendrocytes in the sub-acute an
three neural cell lineages did not significantly differ between the sub-acu
small number of nestin+ neural progenitor cells was detected in the sub
Scale bar: 10 μm in (C).data revealed that the photon count was significantly
proportional to the number of grafted cells in vivo
(Figure 3B).
We next analyzed the survival rate of the grafted
cells on a weekly basis until 42 days after transplant-
ation using BLI (Figure 3C). At 7 days after trans-
plantation, BLI analysis revealed that the survival of
grafted cells was reduced to 12.4 ± 5.6% in the sub-
acute TP group and to almost the same level in the
chronic TP group (15.2 ± 2.9%). At 42 days afterin the sub-acute and chronic TP groups. A, Representative in vivo
ber of NS/PCs and the measured photon count were significantly
BLI of the sub-acute and chronic TP groups immediately and 42 days
nt difference in the survival rate of grafted cells between the sub-
means ± SEM (n = 10). E, GFP+ grafted cells differentiated into Hu+
d chronic TP groups. F, The differentiation rate of grafted cells into the
te and chronic TP groups 42 days after transplantation. Only a
-acute and chronic TP groups. Values are means ± SEM (n = 3).
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vived in both the sub-acute and chronic groups (8.6 ±
2.6% vs. 8.3 ± 1.9%). The survival rate of grafted cells
did not significantly differ between the sub-acute and
chronic TP groups at any time point examined
(Figure 3D).
To evaluate the differentiation phenotype of the grafted
cells in vivo, immunostaining for cell markers was per-
formed 42 days after transplantation for both the sub-acute
and chronic groups. Green fluorescent protein (GFP)+
grafted cells differentiated into all three neural lineages in
both groups (Figure 3E). Quantitative analyses revealed that
in the sub-acute and chronic TP groups, most of the grafted
cells differentiated into GFAP+ astrocytes (60.8 ± 1.6% and
60.7 ± 3.7%), followed by adenomatous polyposis coli anti-
gen (APC)+ oligodendrocytes (20.3 ± 5.1% and 15.3 ± 1.3%)
and Hu+ neurons (11.8 ± 6.0% and 12.4 ± 4.2%). The differ-
entiation rates of neurons, astrocytes, and oligodendrocytes
did not significantly differ between the sub-acute and
chronic TP groups (Figure 3F). Nestin-positive cells repre-
sented around 3% of the grafted cells in both TP groups.
Grafted cells were limited to the lesion epicenter in the
chronic TP group due to extensive glial scar formation
To examine whether the prominent glial scarring seen in
the chronic TP group affected the distribution of graftedFigure 4 Distribution of grafted cells in the sub-acute and chronic TP
sections in the sub-acute and chronic TP groups 42 days after transplantati
Quantitative analysis of the GFP+ grafted cell area in axial sections 42 days
rostral, and caudal sites in the sub-acute TP group, whereas they were limi
± SEM (n = 4). *P < 0.05. D, Representative images of GFP- and CS56-immu
E, Higher-magnification images of the boxed area in (D). In the sub-acute T
to less accumulation of CS56+ CSPG around the lesion site, while the robus
TP group. Scale bar: 1000 μm in (A), 100 μm in (B), 500 μm in (D) and 200cells, we performed immunostaining for GFP in both TP
groups. In sagittal sections of the sub-acute TP group, GFP
+ grafted cells were found at the epicenter and at rostral
and caudal sites, whereas in the chronic TP group, grafted
cells were seen almost exclusively at the lesion epicenter
(Figure 4A, B). Quantitative analysis of the GFP+ areas in
the axial sections revealed that the GFP+ area in the sub-
acute TP group, which spread from 3 mm rostral to 2 mm
caudal from the lesion epicenter, was significantly larger
than that in the chronic TP group (Figure 4C). Moreover,
to clarify what causes the difference of distribution of
grafted cells, double immunostaining for GFP and CS56
was performed in both TP groups. The GFP+ grafted cells
were surrounded and enclosed by CS56+ CSPG areas at
the lesion site in the chronic TP group, whereas the grafted
cells distributed beyond CSPGs areas due to less accumula-
tion of CSPG around the lesion site in the sub-acute TP
group (Figure 4D, E).
NS/PC transplantation at the sub-acute phase, but not at
the chronic phase, contributes to the preservation and/or
enhancement of myelination and axonal growth
To compare the effects of NS/PC transplantation on the
injured spinal cord between the sub-acute and chronic
groups, axial sections were examined histologically using
hematoxylin-eosin (HE) staining (Figure 5A). In sectionsgroups. A, Representative images of GFP-immunostained sagittal
on. B, Higher-magnification images of the boxed areas in (A). C,
after transplantation. Grafted cells were located at the epicenter,
ted to the lesion epicenter in the chronic TP group. Values are means
nostained sagittal sections from the sub-acute and chronic TP groups.
P group, the GFP+ grafted cells migrated away from the graft site due
t CSPGs prevented further migration of the grafted cells in the chronic
μm in (E).
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it, the HE-stained images revealed significant atrophy of
the spinal cord in the sub-acute phosphate-buffered sa-
line (PBS) group compared to the sub-acute TP group.
However, the experimental transverse area of the spinal
cord did not significantly differ between the chronic TP
and PBS groups (Figure 5B). In addition, the sub-acute
TP group demonstrated a significantly larger myelinated
area compared to the sub-acute PBS group at the lesion
epicenter and in sections 4 mm rostral and caudal to the
epicenter (Figure 5A), whereas the myelinated area did
not significantly differ between the chronic TP and PBS
groups (Figure 5C).
Next, to investigate axonal growth after NS/PC trans-
plantation, immunostaining for 200 kDa neurofilament
(NF-H) and 5-hydroxytryptamine (5HT) was performed
in all experimental groups (Figure 5D). The NF-H+ areas
at the lesion site as well 4 mm rostral and caudal to it
significantly differed between the sub-acute TP group
and the other groups (Figure 5E). Furthermore, the sub-
acute TP group demonstrated a significantly larger areaFigure 5 Comparison of the effects of NS/PC transplantation between
LFB-stained images of axial sections at the lesion epicenter in the sub-acut
spinal cords was observed in the chronic TP and control groups compared
*P < 0.05. C, The sub-acute TP group demonstrated a significantly larger m
means ± SEM (n = 3). *P < 0.05. D, Representative images of sagittal sectio
sections stained for 5HT at the lumbar intumescence in the sub-acute TP, c
fibers was observed in the sub-acute TP group than in the chronic TP g
**P < 0.01. F, Significantly larger areas of 5HT+ serotonergic fibers were d
control groups. Values are means ± SEM (n = 3). **P < 0.01. Scale bar: 1of 5HT+ serotonergic fibers in the distal cord compared
to the other three groups (Figure 5F). By contrast, the
chronic TP group demonstrated no significant differ-
ences in the NF-H+ and 5HT+ areas compared to the
chronic PBS group.
NS/PC transplantation at the sub-acute phase, but not at
the chronic phase, promotes motor function and
electrophysiological recovery after SCI
Finally, we evaluated locomotor functional recovery by
Basso Mouse Scale (BMS) score, Rotarod testing, and
DigiGait. We confirmed that the mice exhibited
complete paralysis of the hindlimbs by a BMS score of
0 at 1 DPI. At 7 DPI, the hind limb locomotor func-
tions had recovered spontaneously to an approximate
BMS score of 2, and plateaued at an approximate BMS
score of 3, in all experimental groups except the sub-
acute TP group. In the sub-acute TP group, significantly
greater functional recovery was observed compared to
the sub-acute PBS group at 14 DPI and thereafter. By
contrast, the chronic TP group did not show anythe sub-acute and chronic TP groups. A, Representative HE- and
e TP, chronic TP, and both control groups. B, Significant atrophy of the
to that of the sub-acute TP group. Values are means ± SEM (n = 3).
yelinated area than the chronic TP and control groups. Values are
ns stained for NF-H at the rim of the lesion epicenter and of axial
hronic TP, and each control group. E, Greater area of NF-H+ neuronal
roup or control groups. Values are means ± SEM (n = 3). *P < 0.05,
etected in the sub-acute TP group than in the chronic TP or
00 μm in (A) and (D).
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those of the chronic PBS group (Figure 6A).
The gait performance of the mice in each group was ana-
lyzed using the DigiGait system at 42 days after cell trans-
plantation or PBS injection. In both PBS control groups
and the chronic TP group, a subset of experimental ani-
mals (2 of 10 mice in each group) were unable to walk suf-
ficiently well on a treadmill moving at 7 cm/s to perform
the test, but all the mice in the sub-acute TP group could
perform the test. Gait analysis revealed a significantly
longer stride length in the sub-acute TP group than in the
sub-acute PBS group, whereas no significant difference in
stride length was detected between the chronic TP and ei-
ther PBS group (Figure 6B). Consistent with these findings,
in the Rotarod test at 42 days after cell transplantation or
PBS injection, the mice in the sub-acute TP group
remained on the rotating rod for a significantly longer time
than those of the sub-acute PBS group, but no significant
difference was observed between the chronic TP group
and either PBS group (Figure 6C).Figure 6 Motor function and electrophysiological recovery after NS/P
by BMS score. The sub-acute TP group exhibited significantly better functio
whereas no significant difference was observed between the chronic TP gr
**P < 0.01. B, Treadmill gait analysis using the DigiGait system revealed a si
TP group or either control group 42 days after cell transplantation or PBS i
each control n = 8). **P < 0.01. C, The sub-acute TP group walked for a sign
either control group 42 days after cell transplantation or PBS injection. Valu
MEP in the sub-acute TP, chronic TP, and both control groups 42 days afteElectrophysiological examinations performed at 42
days after cell transplantation or PBS injection by
motor-evoked potential (MEP). MEP waves were
detected in all mice of the sub-acute TP group, and the
average signal-to-response latency was 6.1 ± 0.2 ms and
the average first wave amplitude was 134.0 ± 31.5 mv.
However no MEP waves were observed at all in 5 out of
the 7 mice in the chronic TP group and at all mice in
the sub-acute and chronic PBS groups (Figure 6D). Tak-
ing the results of all the motor functional analyses to-
gether, no functional recovery of the hindlimbs was
observed in the chronic TP group.
Discussion
Previous studies have indicated that NS/PC transplant-
ation at the sub-acute phase has therapeutic potential
for SCI [1-7,18]. At the chronic phase, however, NS/PC
transplantation does not result in functional recovery.
Many researchers have sought to improve motor func-
tion in chronic SCI by NS/PC transplantation. However,C transplantation. A, Hindlimb motor function was assessed weekly
nal recovery than the vehicle control group at 14 DPI and thereafter,
oup and the vehicle control group. Values are means ± SEM (n = 10).
gnificantly longer stride in the sub-acute TP group than in the chronic
njection. Values are means ± SEM (sub-acute TP n = 10, chronic TP and
ificantly longer time on the rotating rod than the chronic TP group or
es are means ± SEM (n = 10). **P < 0.01. D, Representative profiles of
r cell transplantation or PBS injection.
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and no consensus exists concerning the survival and/
or fate of grafted cells in chronic-phase transplantation
[9-12]. For example, some reports demonstrated that
cells grafted at the chronic phase of SCI have a poor
survival rate [9,12], while Cusimano et al. reported no
significant difference in survival rate between NS/PC
transplantation at the sub-acute versus the chronic
phase [11]. However, these findings were based on
histological examinations only. To clarify this issue, we
performed sub-acute- and chronic-phase transplanta-
tions of NS/PCs derived from transgenic mice that
ubiquitously express ffLuc-cp156 on a C57BL/6J back-
ground [14] to treat SCI in adult mice. These NS/PCs
showed strong bioluminescent and fluorescent signals
originating from ffLuc-cp156 [14], enabling the easy
detection of surviving grafted cells in living animals
noninvasively by BLI [4,13] and confirmation of inte-
grated cells within the injured spinal cord by immuno-
histology for GFP without using a lentiviral vector.
Using cells from these mice, we demonstrated that the
NS/PCs grafted during the chronic phase of SCI had a
similar survival rate to those transplanted at the sub-
acute phase. We also observed no significant difference
between the two groups in the differentiation pheno-
types of the grafted cells. The survival and/or differenti-
ation potential of grafted cells can change remarkably
due to microenvironmental changes in the injured spinal
cord [19]. A previous study showed that grafted NS/PCs
mainly differentiate into astrocytes after transplantation
at the acute phase [4]. Inflammatory cytokines, such as
IL-1β, IL-6, and TNF-α, also increase dramatically in
the injured spinal cord during the acute phase [20,21],
and these cytokines induce NS/PCs to differentiate
into astrocytes. Moreover, growth factors affect the
fate of grafted NS/PCs. For example, EGF, FGF, NT3,
and PDGF have demonstrated beneficial effects on
the survival of NS/PCs [10,12,22]. HGF and PDGF pro-
mote neuronal differentiation [23,24], whereas CNTF
enhances glial differentiation in vitro [25]. To assess
microenvironmental changes in the injured spinal cord,
we performed a microarray analysis to exhaustively com-
pare the gene expression profiles between the sub-acute
and chronic phases of SCI. The expression levels of all
cytokines and growth factors did not significantly differ,
consistent with our BLI and histological results on the
survival and/or fate of the grafted cells. These data sug-
gested that the microenvironments of the injured spinal
cord were not significantly different at the sub-acute and
chronic SCI phases with respect to the expression of fac-
tors known to influence the survival rate and differenti-
ation of grafted NS/PCs.
Many reports concern possible mechanisms under-
lying the therapeutic effects of NS/PC transplantationfor SCI; for example, grafted cells contribute to the re-
construction of neural circuits and remyelination
[2,6,17,26]. NS/PCs also secrete neurotrophic factors,
which support the survival of host neural cells and en-
hance axonal growth and angiogenesis [27-30]. In this
study, motor function recovery was observed in the sub-
acute TP group, but not in the chronic TP group. Con-
sistent with this result, more NF-H+ neuronal fibers and
5HT+ serotonergic fibers, which are involved in motor
function recovery [30-32], were observed in the sub-
acute TP group than in the sub-acute PBS group. More-
over, Luxol Fast Blue (LFB) staining revealed signifi-
cantly larger myelinated areas in the sub-acute TP group
than in the sub-acute PBS group. By contrast, no signifi-
cant differences in NF-H+ neuronal fibers, 5HT+ seroto-
nergic fibers, or LFB+ myelinated areas were observed
between the chronic TP and chronic PBS groups. Fur-
thermore, no MEP waves were detected in most mice in
the chronic TP group.
As a possible reason for these findings, we refer to the
poor migration of grafted cells in the chronic TP group.
Since glial scar formation prevented grafted NS/PCs
from migrating away from the graft site and integrating
with the host spinal cord, the regeneration of neural cir-
cuits, remyelination, and/or preservation of host neural
cells did not occur in areas rostral and caudal to the
injured spinal cord of the chronic TP group. Consistent
with this scenario, many previous reports indicate that
insufficient migration of grafted cells results in poor
functional recovery after SCI [33,34].
Our microarray and histological analyses suggested
that more macrophages or microglial cells, including a
substantial number of M2 macrophages, were distribu-
ted around the lesion epicenter at the sub-acute phase
than at the chronic phase. In agreement with this find-
ing, previous studies have reported that infiltration of
macrophages and microglial cells peaks at approximately
7 DPI [35,36]. Moreover, M2 macrophages have an anti-
inflammatory role and promote axonal growth after SCI
[37-39], and their phagocytic activity was shown to con-
tribute to tissue repair in the injured CNS by reducing
myelin debris [40-42]. In addition, Busch et al. demon-
strated that activated macrophages induced axonal die-
back in the injured CNS [43], which was prevented by
switching the infiltrating macrophages from M1 to M2
phenotype [39]. Furthermore, grafted NS/PCs also exert
immunomodulatory effects through interactions with in-
filtrating immune cells [44,45]. Especially in the sub-
acute phase, grafted NS/PCs can affect the properties of
infiltrating macrophages, inducing their shift from M1
to M2 in the injured spinal cord [11,39]. Therefore, NS/
PCs transplanted at the sub-acute stage may alter the
microenvironment to favor M2, resulting in a synergistic
effect that supports the increase in neuronal fibers and
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immunomodulatory strategy, such as the administration
of a mediator of phenotypic switching from M1 to M2
or the combined transplantation of NS/PCs and M2
macrophages, may have therapeutic potential in chronic
SCI. In contrast, previous studies reported that M1
macrophages impairs recovery of SCI through the pro-
duction of oxidative metabolites or pro-inflammatory
cytokines including TNF-α, which induced the apoptotic
cell death of neural precursor cells [42,46,47]. However,
the expressions of genes associated with M1 macro-
phages showed no significant difference among the sub-
acute and chronic phases. These findings are consistent
with the similar survival rate of the grafted NS/PCs in
both TP groups.
Taken together, these results suggest that during the
chronic phase of SCI, the injured spinal cord micro-
environment appears to be unfavorable for the thera-
peutic mechanisms of NS/PC transplantation, owing to
extensive glial scarring [48] and/or the phenotype of in-
filtrating macrophages. Accordingly, to improve the
therapeutic potential of NS/PC transplantation per-
formed at the chronic phase, altering the microenviron-
ment in the injured spinal cord is likely to be important.
For example, suppression of axonal growth inhibitors
may improve the microenvironment. CSPGs, which are
the most prevalent axonal growth inhibitors, are pro-
duced by reactive astrocytes and involved in glial scar-
ring [48]. Chondroitinase ABC (ChABC), which digests
CSPG, promotes axonal growth and the migration of
grafted NS/PCs [49,50]. Karimi-Abdolrezaee et al.
described that CSPGs hinder the survival of grafted cells
and the combined therapy of ChABC administration and
NS/PCs transplantation promotes the migration and in-
tegration of grafted cells [51]. While our data demon-
strated that CSPGs prevent the migration of grafted
cells, but show no influence on their survival, we have
great hopes that a combination of NS/PC transplant-
ation and the administration of a suppressor of axonal
growth inhibitor may be effective for inducing functional
recovery in chronic SCI.
Conclusions
Microenvironmental changes in SCI affect the survival
and/or fate of NS/PCs grafted into the injured spinal
cord. The survival rate and differentiation phenotype of
grafted cells were similar between chronic-phase and
sub-acute-phase transplantation, with no significant dif-
ference in the secretion of cytokines and growth factors
in the host environment between the two phases. How-
ever, the distribution of grafted cells was restricted by
the robust glial scar that formed around the lesion epi-
center at the chronic phase. Consequently, no functional
recovery was observed in this phase. Additionally, in thesub-acute phase, M2 macrophages, which infiltrated pre-
dominantly in this phase, might contribute to the func-
tional repair upon NS/PC transplantation. Alteration of
the microenvironment in SCI, focusing on the glial scar
and the inflammatory phenotype, appears to be the best
possible solution to maximize the therapeutic potential
of NS/PC transplantation in the chronic phase.
Methods
NS/PC culture and analysis
NS/PCs were cultured and expanded, as previously
reported [52]. Briefly, the striata of transgenic mice ubi-
quitously expressing ffLuc-cp156, a fusion protein of
firefly luciferase and a circularly permuted Venus protein
[14], were dissociated using a fire-polished glass pipette
on embryonic day 14. Venus is a fluorescent protein
with fast and efficient maturation that was originally
engineered from GFP [53], and therefore grafted cells
can be detected as fluorescent Venus signals using anti-
GFP antibody [17,26]. Dissociated cells were collected by
centrifugation and re-suspended in culture medium,
which consisted of Dulbecco’s modified Eagle medium/
F12 (Sigma-Aldrich, St. Louis, MO, USA) supplemented
with a previously described hormone mixture [52]. Human
recombinant FGF-2 (Peprotech, Rocky Hill, NJ, USA) and
EGF (Peprotech) (20 ng/ml each) were added every 2 days.
The cells formed floating cell clusters (neurospheres)
within 2–3 days. After propagation for 3 passages, the neu-
rospheres were used for in vitro BLI, differentiation, and
proliferation assays, and for cell transplantation.
For differentiation analysis, the neurospheres were plated
onto poly-L-ornithine/fibronectin-coated 8-well chamber
slides (Iwaki; Asahi Glass Co Ltd., Tokyo, Japan) at a dens-
ity of 1 × 105 cells/ml and cultured in culture medium
without serum or growth factors at 37°C in 5% CO2 and
95% air for 7 days. The differentiated cells were then fixed
with 4% paraformaldehyde in 0.1 M PBS and stained with
the following primary antibodies for immunocytochem-
istry: anti-Tuj-1 (mouse IgG, 1:1000, Sigma-Aldrich), anti-
GFAP (rat IgG, 1:1000, Invitrogen, Carlsbad, CA, USA),
and anti-CNPase (mouse IgG1, 1:1000, Sigma-Aldrich).
Nuclei were stained with Hoechst 33258 (10 μg/ml, Sigma-
Aldrich). In vitro images were obtained using a fluores-
cence microscope (BZ-9000; Keyence Co., Osaka, Japan).
The proliferation assay was performed by measuring
ATP, which indirectly reflects the number of viable
cells [15,17,54]. In brief, NS/PCs were first incubated
in culture medium without serum or growth factors
in 48-well cell-culture plates (Corning Inc., Corning,
NY, USA) at 37°C in 5% CO2 and 95% air for 24 or
72 h. D-luciferin was then added to each well, and the
luminescent signal was detected immediately using a
Xenogen-IVIS spectrum cooled charged-coupled device
(CCD) optical macroscopic imaging system (Caliper Life
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lation doubling time, the ATP assay was modified, as
described elsewhere [15,17,54].
SCI model
Adult female C57BL/6J mice (8–10 weeks old, 18–22 g,
n = 52; Clea, Tokyo, Japan) were anesthetized with an
intraperitoneal (i.p.) injection of ketamine (100 mg/kg)
and xylazine (10 mg/kg). After laminectomy at the 10th
thoracic spinal vertebra (Th10), the dorsal surface of the
dura mater was exposed. Contusive SCI was induced
using a commercially available SCI device (IH Impactor,
Precision Systems and Instrumentation, Lexington, KY,
USA), as previously described [4]. This device creates a
reliable contusion injury by rapidly applying a force-
defined impact (60 kdyn) with a stainless steel-tipped im-
pactor. All experiments were approved by the ethics
committee of Keio University and fully in accordance with
the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health, Bethesda, MD, USA).
Microarray analysis
The injured mice were anesthetized and transcardially
perfused with heparinized saline (5 U/ml) at 9 DPI or 42
DPI (n = 3 each). Dissected segments of spinal cord at
the Th10 level were rapidly frozen and placed in TRIzol
(Invitrogen). Total RNA was isolated using an RNeasy
Mini Kit (Qiagen Inc., Hilgen, Germany), in accordance
with the manufacturer’s instructions. As a control, sam-
ples of naïve spinal cord were harvested by the same
protocol. For microarray analysis, RNA quality was
assessed using a 2100 Bioanalyzer (Agilent Technologies
Inc., Santa Clara, CA, USA), and 100 ng of total RNA
was reverse transcribed, biotin labeled, and hybridized to
a GeneChipW Mouse Genome 430 2.0 Array (Affymetrix
Inc., Santa Clara, CA, USA). The array was then washed
and stained in a Fluidics Station 450, according to the
manufacturer’s instructions [55,56]. The microarrays
were scanned using a GeneChip Scanner 3000 7G, and
the raw image files were converted to normalized signal
intensity values using the MAS 5.0 algorithm. PCA was
carried out with Gene Spring GX software (Agilent
Technologies Inc.), using the full set of normalized data.
For the clustering analysis, the normalized data were
narrowed down by the cut-off values of expression levels
(>50) and by fold change (>1.5, versus the signal of in-
tact spinal cord), and statistical analysis was performed
using one-way ANOVA followed by the Tukey-Kramer
test (P < 0.05). The heat map was visualized with Gene
Spring GX.
NS/PC transplantation
Various numbers of NS/PCs (approximate range 2.5 ×
104 to 5 × 105 cells/2 μl) were transplanted intouninjured naïve mice (n = 3, each), and NS/PCs (5 × 105
cells/2 μl) were transplanted at 9 DPI (sub-acute TP
group, n = 10) or 42 DPI (chronic TP group, n = 10) as
previously reported [4,16,17,26,30,57]. The NS/PCs were
transplanted into the lesion epicenter with a glass micro-
pipette at a rate of 1 μl/min using a Hamilton syringe
(25 μl) and a stereotaxic microinjector (KDS 310, Muro-
machikikai Co. Ltd., Tokyo, Japan). PBS (2 μl) was simi-
larly injected into the lesion epicenter of the control
mice at each time point (sub-acute and chronic PBS
groups, n = 10 each).
Bioluminescence imaging
A Xenogen-IVIS spectrum CCD optical macroscopic im-
aging system was used for in vitro and in vivo BLI as
previously reported [4,16,17]. In brief, the signal inten-
sity of NS/PCs in vitro was assessed using plated cells at
various cell numbers (approximate range 1 × 102 to 1 ×
104 cells/well), and BLI was performed immediately after
adding D-luciferin (150 μg/ml) (n = 3). The integration
time was fixed at 1 min for each image.
In vivo imaging was performed 15 min after the i.p. in-
jection of D-luciferin (0.3 mg/g body weight) with the
field-of-view set at 13.2 cm, because the photon count
was most stable during this period. The intensity peaked
between 10 and 30 min after the i.p. injection of D-luci-
ferin. The integration time was fixed at 5 min for each
image. All images were analyzed with Living Image soft-
ware (Caliper Life Sciences), and the optical signal inten-
sity was expressed as photon flux (photon count) in
units of photons/s/cm2/steradian. Each result was dis-
played as a pseudo-colored photon count image super-
imposed on a gray-scale anatomic image. To quantify
the measured light, a region of interest was defined in
the cell-implanted area, and all values at the same region
of interest were examined.
Behavioral analyses
The motor function of each mouse was evaluated weekly
using the BMS up to 49 DPI in the sub-acute TP and
PBS groups and up to 84 DPI in the chronic TP and
PBS groups (n = 10 per group) [58]. This assessment
was performed by two investigators blinded to the iden-
tity of the experimental mice.
Motor coordination was evaluated using a rotating rod
apparatus (Rotarod, Muromachikikai Co., Ltd.), which
consisted of a plastic rod (3 cm diameter, 8 cm length)
with a gritted surface flanked by two large discs (40 cm
diameter) (n = 10 per group). At 42 days after cell trans-
plantation or PBS injection, each mouse was placed on
the rod while it rotated at 20 rpm for 2 min sessions
[59]. Three trials were conducted, and the maximum
number of seconds the mouse stayed on the rod was
recorded.
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(Mouse Specifics, Quincy, MA, USA) (n = 10 per group)
[17,26,60]. Each mouse demonstrated weight-supported
hindlimb stepping at 42 days after cell transplantation or
PBS injection. The stride length was determined on a
treadmill set to a speed of 7 cm/s.
Electrophysiology
Electrophysiological experiments were performed using
a Neuropack S1 MEB-9402 (Nihon Kohden, Tokyo,
Japan) at 42 days after cell transplantation or PBS injec-
tion (n = 7 per group) [26]. The animals were anesthe-
tized with an i.p. injection of ketamine (60 mg/kg) and
xylazine (6 mg/kg), and the stimulation was applied
through the occipitocervical area of the spinal cord and
the hindlimb by needle electrodes. The active electrode
was placed in the quadriceps muscle belly, and the refer-
ence electrode was placed near the distal quadriceps ten-
don. The ground electrode was placed on the tail. A
stimulus of 0.4 mA intensity, 0.2 ms duration, and 1 Hz
interstimulus interval were used. The latency was mea-
sured as the length of time from the stimulus to the
onset of first response wave. The amplitude was mea-
sured from the initiation point of the first response wave
to its highest point.
Histological analyses
Injured animals were deeply anesthetized and transcar-
dially perfused with 4% PFA in 0.1 M PBS at 9 DPI or
42 DPI (n = 3 each). The treated animals were similarly
prepared 42 days after cell transplantation or PBS injec-
tion. The spinal cords were removed, postfixed overnight
in 4% PFA, soaked overnight in 10% sucrose, followed by
30% sucrose, embedded in Optimal Cutting Temperature
compound (Sakura Finetechnical Co., Ltd., Tokyo,
Japan), frozen, and sectioned in the sagittal or axial plane
at 12 μm thickness on a cryostat (CM3050 S; Leica
Microsystems, Wetzlar, Germany). The injured spinal
cord sections were histologically evaluated by HE stain-
ing and immunohistochemistry, followed by quantitative
analysis. The sections of transplanted spinal cord were
subjected to HE staining, LFB staining, and immunohis-
tochemistry followed by quantitative analyses.
For immunohistochemistry, tissue sections were stained
with the following primary antibodies: anti-GFP (rabbit
IgG, 1:200; Frontier Institute, Hokkaido, Japan), anti-Hu
(human IgG, 1:1000, a gift from Dr. Robert Darnell, The
Rockefeller University, New York, NY, USA), anti-GFAP
(rat IgG, 1:200, Invitrogen), anti-APC CC-1 (mouse IgG,
1:200; Calbiochem, San Diego, CA, USA), anti-nestin
(mouse IgG1, 1:500; BD Bioscience Pharmingen, San Jose,
California, USA), anti-CS56 (a marker for CSPG, mouse
IgM, 1:200; Sigma-Aldrich), anti-Iba1 (a marker for micro-
glia/macrophages, rabbit IgG, 1:200; Wako Pure ChemicalIndustries, Osaka, Japan), anti-arginase-1 (a marker for M2
macrophages, goat IgG, 1:200; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-LAMP2 (a marker for endo-
somes or lysosomes, rat IgG, 1:200; Abcam, Cambridge,
UK), anti-NF-H (mouse IgG1, 1:200; Chemicon, Millipore,
Billerica, MA, USA), and anti-5HT (goat IgG, 1:200;
Immunostar, Hudson, WI, USA). For immunohistochemis-
try with anti-GFP, -NF-H, and -5HT, a biotinylated second-
ary antibody (Jackson Immunoresearch Laboratory Inc.,
West Grove, PA, USA) was used after exposing the sec-
tions to 0.3% H2O2 for 30 min at room temperature to
inactivate endogenous peroxidases. The signals were
enhanced with the Vectastain ABC kit (Vector Laborator-
ies, Inc., Burlingame, CA, USA). Nuclei were stained with
Hoechst 33258 (10 μg/ml, Sigma-Aldrich). All images
were obtained using a fluorescence microscope (BZ 9000;
Keyence Co.) or a confocal laser scanning microscope
(LSM 700; Carl Zeiss, Munich, Germany).
Quantitative analyses
Quantitative analyses of the histological findings (HE,
LFB staining, and immunostaining for CS56, Iba1, NF-H,
5HT, GFP/each phenotypic marker, and arginase-1/Iba1)
were performed using a BZ 9000 microscope and Dy-
namic Cell Count BZ-HIC software (Keyence Co.). The
threshold values were maintained at a constant level for
all analyses. The GFP+ area was quantified using images
of axial sections of the lesion epicenter and 0.5 mm, 1.0
mm, 2.0 mm, 3.0 mm, and 4.0 mm rostral and caudal to
the epicenter at 100× magnification (n = 4 each). To de-
termine the spinal cord area, HE-stained images of axial
sections of the lesion epicenter and 4.0 mm rostral and
caudal to the epicenter at 100× magnification were used
(n = 3 each). Quantitative analysis of the LFB+ area was
similarly performed using axial sections of the lesion epi-
center and 4.0 mm rostral and caudal to the epicenter at
100× magnification (n = 3 each). CS56+ areas as well as
Iba1+ areas were quantified in the midsagittal sections of
injured spinal cords at 100× magnification (n = 3 each).
To quantify NF-H+ fibers, four regions were automat-
ically captured within the midsagittal sections of the le-
sion epicenter and 4.0 mm rostral and caudal to the
epicenter at 400× magnification (n = 3 each). To assess
the 5HT+ fibers, five automatically captured regions
within the axial sections were analyzed at the lumbar
intumescence, which was 6–8 mm caudal to the lesion
epicenter (n = 3 each).
To quantify the proportion of each cell phenotype
among the grafted cells in vivo, five regions were cap-
tured within sagittal sections at 200× magnification
using an LSM 700 confocal laser scanning microscope.
GFP and phenotypic marker double-positive cells were
counted in each section (n = 3 each). To quantify the
infiltrated M2 macrophages in the injured spinal cord,
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was counted within five regions of sagittal sections of
the lesion epicenter at 200× magnification with an LSM
700 confocal laser scanning microscope (n = 3 each).
Statistical analysis
All data are reported as the mean ± SEM. An unpaired
two-tailed Student’s t test was used to evaluate the differ-
ences between groups with respect to microarray gene ex-
pression profile, in vivo BLI analysis, in vivo differentiation
assays, and analyses of the CS56+, Iba1+ and GFP+ areas,
and arginase-1+/Iba1+ cells. One-way ANOVA followed by
the Tukey-Kramer test for multiple comparisons was used
in the analyses of the HE, LFB, NF-H+, and 5HT+ areas
and the Rotarod and DigiGait results. Repeated-measures
two-way ANOVA followed by the Tukey-Kramer test was
used for the BMS analysis. P values < 0.05 were considered
statistically significant.
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